Overview

YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients with acute medical illness.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Darexaban